Harnessing oncogenic signaling to enhance oncolytic virotherapy: Lessons from EPAC-encoding vaccinia virus
Abstract
Oncolytic viruses (OVs) exploit intrinsic features of malignant cells to selectively replicate, spread, and induce tumor destruction while stimulating antitumor immunity. A central paradox of this therapeutic modality is that many of the biological programs that enable tumor progression—immune evasion, resistance to apoptosis, metabolic reprogramming, and enhanced migratory capacity—are also highly permissive to viral infection and dissemination.1 Rather than representing a liability, this overlap between oncogenic and proviral signaling may be deliberately leveraged to enhance OV performance.
Fields of Study & Subjects
Virus-based gene therapy research
Bacteriophages and microbial interactions
Bacterial Cancer Therapy
Publication details
- Journal / source
- Molecular Therapy Oncology
- Volume
- 34
- Issue
- 1
- Pages
- 201165–201165
- Publication date
- 1 March 2026
- Language
- EN